Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer ; volume:28 ; number:9 ; day:22 ; month:6 ; year:2023 ; pages:1207-1217 ; date:9.2023
International journal of clinical oncology ; 28, Heft 9 (22.6.2023), 1207-1217, 9.2023
- Creator
-
Nara, Katsuhiko
Taguchi, Ayumi
Yamamoto, Takehito
Hara, Konan
Tojima, Yuri
Honjoh, Harunori
Nishijima, Akira
Eguchi, Satoko
Miyamoto, Yuichiro
Sone, Kenbun
Mori, Mayuyo
Takada, Tappei
Osuga, Yutaka
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10147-023-02367-1
- URN
-
urn:nbn:de:101:1-2023110913143788646939
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nara, Katsuhiko
- Taguchi, Ayumi
- Yamamoto, Takehito
- Hara, Konan
- Tojima, Yuri
- Honjoh, Harunori
- Nishijima, Akira
- Eguchi, Satoko
- Miyamoto, Yuichiro
- Sone, Kenbun
- Mori, Mayuyo
- Takada, Tappei
- Osuga, Yutaka
- SpringerLink (Online service)
Other Objects (12)
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer